Author(s): Asmaa Sattar Abd, Izzat Al-Rayahi, Raghad H. Hussein

Email(s): asmaasattar334@gmail.com

DOI: 10.52711/0974-360X.2023.00695   

Address: Asmaa Sattar Abd1,2*, Izzat Al-Rayahi1, Raghad H. Hussein1
1College of Health and Medical Technology, Middle Technical University, Baghdad, Iraq.
2Medical City, Ministry of Health and Environment, Baghdad, Iraq.
*Corresponding Author

Published In:   Volume - 16,      Issue - 9,     Year - 2023


ABSTRACT:
CoV-2 infection has become a global issue in healthcare since December 2019. According to our findings, diabetes raises the likelihood and severity of COVID-19 disease in 2019. High blood sugar was found to reduce immunity and worsen COVID-19 while it is linked to several other risk factors. With COVID-19, the study will assess the levels of C3a and C5a in diabetes and non-diabetic patients. This study included 120 covid-19 patients (60 diabetic and 60 non-diabetic). Serum levels were measured in patients and the results showed that the mean levels of C3a and C5a were higher in non-diabetic Covid-19 patients (451.82±108.94 and 215.70±48.37pg/ml respectively) compared with those with diabetes (357.88±41.22 and 188.86±33.98pg/ml respectively) with a significant difference between the two groups (p < 0.001).


Cite this article:
Asmaa Sattar Abd, Izzat Al-Rayahi, Raghad H. Hussein. Complement Anaphylatoxins C3a And C5a in Diabetic and Non-Diabetic Iraqi COVID-19 patients. Research Journal of Pharmacy and Technology 2023; 16(9):4247-0. doi: 10.52711/0974-360X.2023.00695

Cite(Electronic):
Asmaa Sattar Abd, Izzat Al-Rayahi, Raghad H. Hussein. Complement Anaphylatoxins C3a And C5a in Diabetic and Non-Diabetic Iraqi COVID-19 patients. Research Journal of Pharmacy and Technology 2023; 16(9):4247-0. doi: 10.52711/0974-360X.2023.00695   Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2023-16-9-39


REFERENCES:
1.    Lu R. Zhao X. Li J. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet. 2020;395(10224):565-574.
2.    Deng S-Q Peng H-J. Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China. Journal of Clinical Medicine. 2020;9(2):575.
3.    Chen X. Yan J. Caution on kidney dysfunctions of 2019-nCoV patients. medRxiv 2020; 2020.2002.2008.20021212.
4.    Cedzyński M.Thielens NM. Mollnes TE.Vorup-Jensen T. Editorial: The Role of Complement in Health and Disease. Front Immunol. 2019;10:1869.
5.    Al-Rayahi IAM. Machado LR Stover CM. Properdin Is a Modulator of Tumour Immunity in a Syngeneic Mouse Melanoma Model. Medicina (Kaunas). 2021 Jan 21;57(2):85
6.    Hazaratali Panari Vegunarani. M. Study on Complications of Diabetes Mellitus among the Diabetic Patients. Asian J. Nur. Edu. and Research. 2016; 6(2): 171-182.
7.    Ahmadinia PR. Mohammadi TY. Assessment of the risk of Coronary Heart Disease in Diabetes Patients Type-II. Asian J. Nursing Education and Research. 2019; 9(2):267-270.
8.    Patel HP. A Descriptive Study to Assess the Knowledge and Attitude regarding Self Administration of Insulin Injection among Diabetes Mellitus patient in selected Hospital of Visnagar City in view of Information Booklet. Asian Journal of Nursing Education and Research. 2021; 11(4):499-2.
9.    Don Jose K. Femi Sebastian F. Franklin D. Davis Iriene B. Padanilath JJ. A study to assess the Knowledge regarding glycemic control and self- management among diabetic patients in Amala Institute of Medical Sciences Thrissur. Asian Journal of Nursing Education and Research. 2021; 11(4):571-6.
10.    Mohd. YK. Poonam GB. Bihari V. Kumar V. A Review on Diabetes and Its Management. Asian J. Pharm. Res. 3(1): Jan.-Mar. 2013; Page 27-32.
11.    BasmaC.Chaima D. Samir D. Analysis of Risk Factors for Gestational Diabetes in El Oued (Algeria) Population. Asian J. Pharm. Res. 2020; 10(3):177-182.
12.    Roshani B. Akshay P. Dinesh R. Sanjay K. Insulin Therapies: Current and Future Trends. Asian J. Res. Pharm. Sci. 2017; 7(4):189-196.
13.    Vaishnav P. Baludas K. Kavita S. Kalunkhe A. Dadasaheb P. Swati AM. Deepak S. Stress Induced Diabetes. Asian Journal of Research in Pharmaceutical Sciences. 2021; 11(2):145-0.
14.    Naveen KL. Grinton JV. Ananya B. Patient with Diabetes Mellitus and Ocular Complications: A Brief review. Asian Journal of Pharmacy and Technology. 2021; 11(2):141-5.
15.    SivaprasadS. Epidemiological Study on complications of Diabetes and its Treatment Options. Asian Journal of Pharmacy and Technology. 2022; 12(1):38-0.
16.    Afzali B. Noris M. Lambrecht BN. and Kemper C.The state of complement in COVID-19: PMID: 34912108 PMCID: PMC8672651 DOI: 10.1038/s41577-021-00665-1 Free PMC article. www.nature.com/nri. NATURE REVIEWS | Immunology.2021.
17.    Woodruff TM. Shukla AK. The Complement C5a-C5aR1 GPCR Axis in COVID-19 Therapeutics. Trends Immunol. 2020; 41:965–7. doi: 10.1016/ j.it.2020.09.008
18.    Cyprian. FS. Suleman M. Abdelhafez I. Doudin A. et al Complement C5a and Clinical Markers as Predictors of COVID-19 Disease Severity and Mortality in a Multi-Ethnic Population. Original research article Front.Immunol.2021.
19.    Sen S.Chakraborty R. Kalita P. Pathak MP. Diabetes mellitus and COVID-19: Understanding the association in light of current evidence. World J Clin Cases. 2021;9(28):8327-8339.
20.    Espiritu AI. Chiu HHC. Sy MCC. Anlacan VMM. Philippine CORONA Study Group Jamora RDG. The outcomes of patients with diabetes mellitus in The Philippine CORONA Study. Sci Rep. 2021;11(1):24436.
21.    Bwire GM. Coronavirus: Why Men are More Vulnerable to Covid-19 Than Women? SN Compr Clin Med. 2020;2(7):874-876. doi: 10.1007/s42399-020-00341-w. Epub 2020; PMID: 32838138; PMCID: PMC7271824.
22.    Zinellu A. Mangoni AA. Serum Complement C3 and C4 and COVID-19 Severity and Mortality: A Systematic Review and Meta-Analysis With Meta-Regression. Front Immunol. 2021 Jun 7;12:696085.
23.    Risitano AM. Mastellos DC. Huber‐Lang M. et al Complement as a target in COVID‐19? Nat Rev Immunol. 2020; 20(6):343‐344.
24.    Henry BM. Benoit SW.Vikse J. et al. The anti‐inflammatory cytokine response characterized by elevated interleukin‐10 is a stronger predictor of severe disease and poor outcomes than the proinflammatory cytokine response in coronavirus disease 2019 (COVID‐ 19). Clin Chem Lab Med CCLM. 2021;59(3):599‐607.
25.    Magro C. Mulvey JJ. Berlin D. et al Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID‐19 infection: a report of five cases. Transl Res J Lab Clin Med. 2020;220:1‐13.
26.    Gao CA. Bailey JI. Walter JM. et al Highly pathogenic coronavirus N protein aggravates lung injury by MASP‐2‐mediated complement over‐ activation. medRxiv. 2020.
27.    Cyprian FS. Suleman M.Abdelhafez I.Doudin A.MasudDanjuma M. Mir FA.Parray A.et al Complement C5a and Clinical Markers as Predictors of COVID-19 Disease Severity and Mortality in a Multi-Ethnic Population. Front Immunol. 2021;12:707159.
28.    Han M. Ma K. Wang X. Yan W. Wang H. You J. Wang Q Chen H Guo W Chen T Ning Q Luo X. Immunological Characteristics in Type 2 Diabetes Mellitus Among COVID-19 Patients. Front Endocrinol(Lausanne). 2021 ;12:596518.
29.    Critchley JA. Carey IM. Harris T.DeWilde S. Hosking FJ. et al Glycemic control and risk of infections among people with type 1 or type 2 diabetes in a large primary care cohort study. Diabetes Care. 2018; 41:2127–35.


Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

1.3
2021CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available